Gilead's new HIV med, a bird flu shot for chickens, and Hims blood tests: Pharma news roundup

Start Slideshow

Image for article titled Gilead's new HIV med, a bird flu shot for chickens, and Hims does blood tests: Pharma news roundup — Graphic: Images: NurPhoto / Contributor, ANDREW CABALLERO-REYNOLDS, Andrew Harnik / Staff, Hims & Hers/Business Wire

Gilead (GILD) said on Tuesday that the U.S. Food and Drug Administration (FDA) has accepted its application for a twice-yearly injectable drug designed to prevent HIV. The U.S. Department of Agriculture (USDA) granted a conditional license for a vaccine designed to protect chickens from the bird flu, in an effort to contain an outbreak that has sent egg prices soaring. And after cashing in on the weight-loss drug boom, millennial-focused telehealth company Hims & Hers (HIMS) is expanding into at-home blood testing.

Check out those stories and more pharmaceutical news highlights from this week.

Previous Slide

Next Slide

2 / 8

Eli Lilly wants to use its weight loss drug windfall to fight Alzheimer’s and hearing loss

Medical bottles and syringe are seen with Eli Lilly and Company logo displayed on a screen in the background in this illustration photo taken in Krakow, Poland on November 10, 2022.

Image: NurPhoto / Contributor (Getty Images)

The weight-loss drug boom has transformed Eli Lilly (LLY), the maker of Zepbound, into the largest healthcare company in the world. Now, the pharma giant wants to reinvest its success with weight-loss meds into tackling some of the world’s toughest health challenges. Eli Lilly chief scientific officer Dan Skovronsky told CNBC in an interview the the company is now working to tackle diseases like Alzheimer’s, neurodegenerative diseases, heart health and even hearing loss.

Previous Slide

Next Slide

3 / 8

Trump’s tariff threats are hitting these car, chip, and pharma stocks

President Donald Trump escalated trade tensions Tuesday by threatening to impose new 25% tariffs on automobiles, pharmaceuticals, and semiconductors, heightening concerns over a potential trade war. The announcement has sent ripples through financial markets, with investors bracing for potential volatility.

Previous Slide

Next Slide

4 / 8

Big Pharma and drug middlemen donated record money to get Trump on their side

President Donald Trump speaks during an executive order signing in the Oval Office at the White House on February 11, 2025 in Washington, DC.

In the months after the 2024 election and before President Donald Trump’s second inauguration, healthcare executives paid millions of dollars to get the ear of the president. The Wall Street Journal reports that Trump has told associates that he raised roughly $500 million in that time, with the funds being split into his inaugural committee and other accounts, including a political action committee. Healthcare executives were among those who wrote the largest checks to attend fundraising dinners with Trump in an effort to gain favor and influence his healthcare agenda, The Journal reports.

Previous Slide

Next Slide

5 / 8

Hims & Hers is getting into the at-home blood testing business

The acquisition will unlock a new level of personalized healthcare and deliver integrated offerings across nutrition, lifestyle, supplements, and medication.

After having massive success with off-brand weight-loss drugs, the millennial-focused telehealth company Hims & Hers is now expanding its offerings to include at-home blood tests. The company announced today that it has acquired Sigmund NJ, marketed as Trybe Labs, allowing Hims & Hers to offer affordable, at-home blood draws. Through the new tests, customers will be able to get lab work done on a variety of health concerns including hormone levels, cardiac risk, stress markers, cholesterol, liver function, thyroid function, and prostate health.

Previous Slide

Next Slide

6 / 8

A new HIV prevention drug could get FDA approval this year

A sign is posted in front of the Gilead Sciences headquarters on April 29, 2020 in Foster City, California.

Preventing HIV infections could soon be as simple as two shots a year. Gilead announced on Tuesday that the Food and Drug Administration (FDA) has accepted its new drug application for a twice-yearly injectable drug designed to prevent HIV. The FDA has granted the application a priority review, setting a target decision date of June 19, 2025.

Previous Slide

Next Slide

7 / 8

A bird flu vaccine for chickens is on its way

A live poultry market is seen as New York Gov. Kathy Hochul has temporarily shut down poultry markets in New York City, Westchester, Nassau and Suffolk counties, in New York, United States on February 07, 2025.

In a bid to contain a bird flu outbreak that has sent egg prices soaring, the U.S. Department of Agriculture (USDA) last week granted a conditional license for a vaccine designed to protect chickens from the virus. The vaccine was developed by animal health giant Zoetis (ZTS) and received approval last week. In a statement, the company said that it began updating its existing bird flu vaccine in 2022, as outbreaks of the highly contagious virus spread through poultry flocks.

Gilead's new HIV med, a bird flu shot for chickens, and Hims does blood tests: Pharma news roundup

Plus, Trump threatens tariffs on pharmaceuticals, and Eli Lilly sets its eyes on preventing Alzheimer's